# Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

> **NCT04623086** · PHASE4 · COMPLETED · sponsor: **University of Washington** · enrollment: 59 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Insulin Degludec
- **DRUG:** Insulin Glargine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04623086
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-14
- **Primary completion:** 2022-09-07
- **Final completion:** 2023-12-31
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623086, "Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04623086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*